Pacira BioSciences, Inc. (PCRX)
PCRXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$36.46
+0.0300 (+0.08%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $1.46bn
- P/E
- 23.4
- EPS, last 4 quarters
- $1.56
- Dividend yield
- –
- Day range
- –
- 52-week range
- $18.80 to $36.67
- Average volume
- 1.42m
- Previous close
- $36.43
Analysts
9 coveringHold0 buy, 9 hold, 0 sell
Targets a year out average $34.79, -4.6% from here
Earnings
next estimate $0.4700Next report
Sep 2025
+9.5%
Dec 2025
-46.7%
Mar 2026
+3.0%
Jun 2026
+63.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $179.52m | $196.87m | $177.38m | $192.40m |
| Gross profit | $145.24m | $156.57m | $140.96m | $148.24m |
| Operating income | $6.36m | $2.34m | $6.90m | $4.27m |
| Net income | $5.43m | $1.64m | $2.92m | $4.65m |
Last four quarters: revenue $746.16m, margin 2.0%, free cash flow $179.51m
News
8 latest- Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?Zacks · Nov 2, 2026
- Viatris Begins Cash Tender Offer To Acquire Pacira At $36.50 Per Share; Stock Down RTTNews · Oct 30, 2026
- Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings GrowthZacks · Oct 29, 2026
- Pacira BioSciences Consensus Price Target Increased 17.74% to $35.13Fintel · Oct 23, 2026
- Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioZacks · Oct 9, 2026
- Biotech Stocks At 52-Week Highs - PCRX +44% On Acquisition News; MANE+14%, HAE+17%, CON, HSTM RTTNews · Oct 9, 2026
- JP Morgan Upgrades Pacira BioSciences to Neutral from UnderweightFintel · Oct 8, 2026
- Why Pacira BioSciences Skyrocketed TodayThe Motley Fool · Oct 8, 2026
The company
Pacira BioSciences, Inc. (Nasdaq: PCRX) delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has two commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic for post-surgical pain management and ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain. Pacira is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies. Its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- pacira.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.